Gemcitabine and UFTE chemotherapy
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic or Recurrent Colorectal Cancer
Conditions
Metastatic or Recurrent Colorectal Cancer, Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan, Salvage Chemotherapy
Trial Timeline
Jun 1, 2011 → —
NCT ID
NCT01409005About Gemcitabine and UFTE chemotherapy
Gemcitabine and UFTE chemotherapy is a phase 2 stage product being developed by Yuhan for Metastatic or Recurrent Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01409005. Target conditions include Metastatic or Recurrent Colorectal Cancer, Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan, Salvage Chemotherapy.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic or Recurrent Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01409005 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic or Recurrent Colorectal Cancer